## **Report Supplementary Material 9**

Table 6. Faecal immunochemical test sensitivity, specificity, PPV, and NPV for AAs at various thresholds in participants who completed 1-3 tests and had at least one colonic examination performed, by sex

Age at	FIT						AA	FIT				
invite	threshold			Completed			Total	+ve	Sensitivity	Specificity	PPV	NPV
(years)	(µg/g)	Test		FIT a	Tested	l +ve	cases	cases	(95% CI)	(95% CI)	(95% CI)	(95% CI)
				n	n	%	n	n	%	%	%	%
Men	40		1 <sup>st</sup>	3454	246	7.1	311	59	19.0 (14.8 to 23.8)	94.1 (93.2 to 94.9)	24.0 (18.8 to 29.8)	92.1 (91.2 to 93.1)
			$2^{nd}$ c	3184	168	5.3	251	30	12.0 (8.2 to 16.6)	95.3 (94.5 to 96.0)	17.9 (12.4 to 24.5)	92.7 (91.7 to 93.6)
			$3^{rd}$ d	2892	133	4.6	207	23	11.1 (7.2 to 16.2)	95.9 (95.1 to 96.6)	17.3 (11.3 to 24.8)	93.3 (92.3 to 94.2)
		Cumulative	2 tests <sup>e</sup>	3430	414	12.1	310	89	28.7 (23.7 to 34.1)	89.6 (88.5 to 90.6)	21.5 (17.6 to 25.8)	92.7 (91.7 to 93.6)
		test analysis	3 tests $^{\rm f}$	3306	547	16.5	296	112	37.8 (32.3 to 43.6)	85.5 (84.2 to 86.8)	20.5 (17.2 to 24.1)	93.3 (92.3 to 94.2)
		Programme	2 tests <sup>g</sup>	3454	414	12.0	311	89	28.6 (23.7 to 34.0)	89.7 (88.5 to 90.7)	21.5 (17.6 to 25.8)	92.7 (91.7 to 93.6)
		analysis	3 tests $^{\rm h}$	3454	547	15.8	311	112	36.0 (30.7 to 41.6)	86.2 (84.9 to 87.3)	20.5 (17.2 to 24.1)	93.2 (92.2 to 94.0)
	30		1 <sup>st</sup>	3454	292	8.5	311	68	21.9 (17.4 to 26.9)	92.9 (91.9 to 93.7)	23.3 (18.6 to 28.6)	92.3 (91.3 to 93.2)
			2 <sup>nd c</sup>	3139	202	6.4	242	38	15.7 (11.4 to 20.9)	94.3 (93.4 to 95.2)	18.8 (13.7 to 24.9)	93.1 (92.1 to 93.9)
			$3^{rd}$ d	2815	158	5.6	190	29	15.3 (10.5 to 21.2)	95.1 (94.2 to 95.9)	18.4 (12.7 to 25.3)	93.9 (93.0 to 94.8)
		Cumulative	2 tests <sup>e</sup>	3431	494	14.4	310	106	34.2 (28.9 to 39.8)	87.6 (86.4 to 88.7)	21.5 (17.9 to 25.3)	93.1 (92.1 to 93.9)
		test analysis	3 tests $^{\rm f}$	3309	652	19.7	296	135	45.6 (39.8 to 51.5)	82.8 (81.4 to 84.2)	20.7 (17.7 to 24.0)	93.9 (93.0 to 94.8)
		Programme	2 tests <sup>g</sup>	3454	494	14.3	311	106	34.1 (28.8 to 39.6)	87.7 (86.5 to 88.8)	21.5 (17.9 to 25.3)	93.1 (92.1 to 94.0)
		analysis	3 tests $^{\rm h}$	3454	652	18.9	311	135	43.4 (37.8 to 49.1)	83.6 (82.2 to 84.8)	20.7 (17.7 to 24.0)	93.7 (92.8 to 94.6)
	20		1 <sup>st</sup>	3454	366	10.6	311	86	27.7 (22.8 to 33.0)	91.1 (90.0 to 92.1)	23.5 (19.2 to 28.2)	92.7 (91.7 to 93.6)

			2 <sup>nd c</sup>	3067	236	7.7	224	40	17.9 (13.1 to 23.5)	93.1 (92.1 to 94.0)	16.9 (12.4 to 22.4)	93.5 (92.5 to 94.4)
			<b>3<sup>rd</sup></b> d	2714	197	7.3	170	25	14.7 (9.7 to 20.9)	93.2 (92.2 to 94.2)	12.7 (8.4 to 18.2)	94.2 (93.3 to 95.1)
		Cumulative	2 tests <sup>e</sup>	3433	602	17.5	310	126	40.6 (35.1 to 46.3)	84.8 (83.4 to 86.0)	20.9 (17.7 to 24.4)	93.5 (92.5 to 94.4)
		test analysis	3 tests <sup>f</sup>	3316	799	24.1	296	151	51.0 (45.2 to 56.8)	78.5 (77.0 to 80.0)	18.9 (16.2 to 21.8)	94.2 (93.3 to 95.1)
		Programme	2 tests <sup>g</sup>	3454	602	17.4	311	126	40.5 (35.0 to 46.2)	84.9 (83.6 to 86.1)	20.9 (17.7 to 24.4)	93.5 (92.5 to 94.4)
		analysis	3 tests <sup>h</sup>	3454	799	23.1	311	151	48.6 (42.9 to 54.3)	79.4 (77.9 to 80.8)	18.9 (16.2 to 21.8)	94.0 (93.0 to 94.8)
	10		1 <sup>st</sup>	3454	536	15.5	311	110	35.4 (30.1 to 41.0)	86.4 (85.2 to 87.6)	20.5 (17.2 to 24.2)	93.1 (92.1 to 94.0)
			2 <sup>nd</sup> c	2898	310	10.7	200	47	23.5 (17.8 to 30.0)	90.3 (89.1 to 91.3)	15.2 (11.4 to 19.6)	94.1 (93.1 to 95.0)
			3 <sup>rd</sup> d	2479	246	9.9	142	27	19.0 (12.9 to 26.4)	90.6 (89.4 to 91.8)	11.0 (7.4 to 15.6)	94.8 (93.9 to 95.7)
		Cumulative	2 tests <sup>e</sup>	3434	846	24.6	310	157	50.6 (44.9 to 56.3)	77.9 (76.4 to 79.4)	18.6 (16.0 to 21.3)	94.1 (93.1 to 95.0)
		test analysis	3 tests <sup>f</sup>	3325	1092	32.8	299	184	61.5 (55.8 to 67.1)	70.0 (68.3 to 71.6)	16.8 (14.7 to 19.2)	94.8 (93.9 to 95.7)
		Programme	2 tests <sup>g</sup>	3454	846	24.5	311	157	50.5 (44.8 to 56.2)	78.1 (76.6 to 79.5)	18.6 (16.0 to 21.3)	94.1 (93.1 to 95.0)
		analysis	3 tests h	3454	1092	31.6	311	184	59.2 (53.5 to 64.7)	71.1 (69.5 to 72.7)	16.8 (14.7 to 19.2)	94.6 (93.6 to 95.5)
Women	40		1 <sup>st</sup>	1745	80	4.6	132	19	14.4 (8.9 to 21.6)	96.2 (95.2 to 97.1)	23.8 (14.9 to 34.6)	93.2 (91.9 to 94.4)
			2 <sup>nd</sup> c	1653	65	3.9	112	8	7.1 (3.1 to 13.6)	96.3 (95.2 to 97.2)	12.3 (5.5 to 22.8)	93.5 (92.1 to 94.6)
			<b>3<sup>rd</sup></b> d	1537	49	3.2	101	13	12.9 (7.0 to 21.0)	97.5 (96.5 to 98.2)	26.5 (14.9 to 41.1)	94.1 (92.8 to 95.2)
		Cumulative	2 tests <sup>e</sup>	1733	145	8.4	131	27	20.6 (14.0 to 28.6)	92.6 (91.2 to 93.9)	18.6 (12.6 to 25.9)	93.5 (92.1 to 94.6)
		test analysis	3 tests <sup>f</sup>	1682	194	11.5	128	40	31.3 (23.4 to 40.0)	90.1 (88.5 to 91.5)	20.6 (15.2 to 27.0)	94.1 (92.8 to 95.2)
		Programme	2 tests <sup>g</sup>	1745	145	8.3	132	27	20.5 (13.9 to 28.3)	92.7 (91.3 to 93.9)	18.6 (12.6 to 25.9)	93.4 (92.1 to 94.6)
		analysis	3 tests <sup>h</sup>	1745	194	11.1	132	40	30.3 (22.6 to 38.9)	90.5 (88.9 to 91.8)	20.6 (15.2 to 27.0)	94.1 (92.8 to 95.2)
	30		1 <sup>st</sup>	1745	94	5.4	132	20	15.2 (9.5 to 22.4)	95.4 (94.3 to 96.4)	21.3 (13.5 to 30.9)	93.2 (91.9 to 94.4)
			2 <sup>nd c</sup>	1639	74	4.5	111	12	10.8 (5.7 to 18.1)	95.9 (94.8 to 96.9)	16.2 (8.7 to 26.6)	93.7 (92.4 to 94.8)
			3 <sup>rd</sup> d	1515	62	4.1	97	15	15.5 (8.9 to 24.2)	96.7 (95.6 to 97.6)	24.2 (14.2 to 36.7)	94.4 (93.0 to 95.5)
		Cumulative	2 tests <sup>e</sup>	1733	168	9.7	131	32	24.4 (17.3 to 32.7)	91.5 (90.0 to 92.8)	19.0 (13.4 to 25.8)	93.7 (92.4 to 94.8)
		test analysis	3 tests <sup>f</sup>	1683	230	13.7	129	47	36.4 (28.1 to 45.4)	88.2 (86.5 to 89.8)	20.4 (15.4 to 26.2)	94.4 (93.0 to 95.5)

		Programme	2 tests <sup>g</sup>	1745	168	9.6	132	32	24.2 (17.2 to 32.5)	91.6 (90.1 to 92.9)	19.0 (13.4 to 25.8)	93.7 (92.3 to 94.8)
		analysis	3 tests h	1745	230	13.2	132	47	35.6 (27.5 to 44.4)	88.7 (87.0 to 90.2)	20.4 (15.4 to 26.2)	94.4 (93.1 to 95.5)
	20		1 <sup>st</sup>	1745	126	7.2	132	25	18.9 (12.6 to 26.7)	93.7 (92.4 to 94.9)	19.8 (13.3 to 27.9)	93.4 (92.1 to 94.6)
			$2^{nd}$ c	1610	95	5.9	106	14	13.2 (7.4 to 21.2)	94.6 (93.4 to 95.7)	14.7 (8.3 to 23.5)	93.9 (92.6 to 95.1)
			$3^{rd}$ d	1468	70	4.8	90	15	16.7 (9.6 to 26.0)	96.0 (94.8 to 97.0)	21.4 (12.5 to 32.9)	94.6 (93.3 to 95.8)
		Cumulative	2 tests <sup>e</sup>	1736	221	12.7	131	39	29.8 (22.1 to 38.4)	88.7 (87.0 to 90.2)	17.6 (12.9 to 23.3)	93.9 (92.6 to 95.1)
		test analysis	3 tests $^{\rm f}$	1689	291	17.2	129	54	41.9 (33.2 to 50.9)	84.8 (82.9 to 86.6)	18.6 (14.3 to 23.5)	94.6 (93.3 to 95.8)
		Programme	2 tests <sup>g</sup>	1745	221	12.7	132	39	29.5 (21.9 to 38.1)	88.7 (87.1 to 90.2)	17.6 (12.9 to 23.3)	93.9 (92.6 to 95.0)
		analysis	3 tests $^{\rm h}$	1745	291	16.7	132	54	40.9 (32.4 to 49.8)	85.3 (83.5 to 87.0)	18.6 (14.3 to 23.5)	94.6 (93.3 to 95.7)
	10		1 <sup>st</sup>	1745	206	11.8	132	37	28.0 (20.6 to 36.5)	89.5 (87.9 to 91.0)	18.0 (13.0 to 23.9)	93.8 (92.5 to 95.0)
			2 <sup>nd c</sup>	1531	131	8.6	94	18	19.1 (11.8 to 28.6)	92.1 (90.6 to 93.5)	13.7 (8.4 to 20.8)	94.6 (93.3 to 95.7)
			$3^{rd}$ d	1358	101	7.4	74	15	20.3 (11.8 to 31.2)	93.3 (91.8 to 94.6)	14.9 (8.6 to 23.3)	95.3 (94.0 to 96.4)
		Cumulative	2 tests <sup>e</sup>	1737	337	19.4	131	55	42.0 (33.4 to 50.9)	82.4 (80.5 to 84.3)	16.3 (12.5 to 20.7)	94.6 (93.3 to 95.7)
		test analysis	3 tests $^{\rm f}$	1695	438	25.8	129	70	54.3 (45.3 to 63.1)	76.5 (74.3 to 78.6)	16.0 (12.7 to 19.8)	95.3 (94.0 to 96.4)
		Programme	2 tests <sup>g</sup>	1745	337	19.3	132	55	41.7 (33.2 to 50.6)	82.5 (80.6 to 84.3)	16.3 (12.5 to 20.7)	94.5 (93.2 to 95.7)
		analysis	3 tests <sup>h</sup>	1745	438	25.1	132	70	53.0 (44.2 to 61.8)	77.2 (75.1 to 79.2)	16.0 (12.7 to 19.8)	95.3 (94.0 to 96.3)

PPV, positive predictive value; NPV, negative predictive value; AA, advanced adenoma; FIT, faecal immunochemical test; +ve, positive; CI, confidence interval.

- a. Participants were not included as invited to any subsequent tests following a FIT positive test at the specified threshold.
- b. Advanced adenomas were defined as adenomas (namely an adenoma, serrated adenoma, or mixed hyperplastic/dysplastic adenoma) which satisfied at least one of the following criteria: (1) ≥ 10mm in size or (2) tubulovillous or villous histology or (3) high grade dysplasia.
- c. The round at which a participant completed their second FIT; for a particular participant this could be round 2 or round 3.
- d. The round at which a participant completed their third FIT; equivalent to round 3 in participants who completed FIT at both prior rounds.
- e. Includes participants who completed at least two rounds of FIT or who were FIT positive at round 1; participants were classed as positive if FIT was positive at either of the first two rounds at which they completed FIT.
- f. Includes participants who completed all three rounds of FIT or who were FIT positive at any round; participants were classed as positive if FIT was positive at any of the three rounds.

- g. Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at either of the first two rounds at which they completed FIT.
- h. Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at any of the three rounds.